SOURCE-LINKED STUDY SUMMARY
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Abstract summarizedQuality not appraised
- What was studied
- Translational research examined eloralintide, an amylin receptor agonist, for obesity, combining laboratory experiments with an early randomized, blinded, placebo-controlled trial.
- Who / model studied
- Experiments used receptor-expressing cells, rats and monkeys; the human trial included 48 healthy participants with mean BMI 27.5.
- Studied dose & schedule
- The human trial tested single ascending doses of 0.04–12 mg against placebo, with body-weight outcomes reported at week 4; administration route was not specified.
- What the study found
- Human receptor assays favored AMY1R. At week 4, weight changed by -2.5% after 4 mg and -4.4% after 12 mg versus +0.6% with placebo. Nine participants reported 16 adverse events, mostly mild, including one moderate vomiting event. Fat-mass loss was demonstrated in obese rats.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.molmet.2025.102271